找回密碼
 To register

QQ登錄

只需一步,快速開始

掃一掃,訪問微社區(qū)

打印 上一主題 下一主題

Titlebook: Mechanical Circulatory Support for Advanced Heart Failure; A Texas Heart Instit Jeffrey A. Morgan,Andrew B. Civitello,O.H. Frazier Book 201

[復制鏈接]
樓主: 小巷
31#
發(fā)表于 2025-3-26 21:44:09 | 只看該作者
32#
發(fā)表于 2025-3-27 02:45:32 | 只看該作者
Who Is an Appropriate Candidate for Long-Term MCS?: The Art of Patient Selection,t is the leading cause of morbidity and mortality, with 50% mortality within 5?years of diagnosis [.]. Approximately less than 10% of this population will progress to advanced HF. These patients experience poor quality of life, frequent hospitalizations, and a 1-year mortality of 25–50% [2, 3]. Adva
33#
發(fā)表于 2025-3-27 07:46:50 | 只看該作者
34#
發(fā)表于 2025-3-27 09:29:15 | 只看該作者
35#
發(fā)表于 2025-3-27 13:59:16 | 只看該作者
36#
發(fā)表于 2025-3-27 20:53:43 | 只看該作者
LVAD Surgical Implant Technique: Infradiaphragmatic Approach, Despite the evolution to continuous flow devices, this technique has remained popular. However, an apical location can make patients vulnerable to arrhythmias and obstruction due to interaction with the ventricular septum. We developed a method for implanting the HeartMate II, HVAD, and HM3 LVAD al
37#
發(fā)表于 2025-3-27 22:24:23 | 只看該作者
38#
發(fā)表于 2025-3-28 03:09:25 | 只看該作者
39#
發(fā)表于 2025-3-28 08:08:09 | 只看該作者
Management of Fluid Balance and Perioperative Renal Complications,ure. Renal and liver dysfunctions often improve after left ventricular assist device placement, but complications in the postoperative period—especially hemodynamic instability, considerable blood loss and blood product replacement, prolonged cardiopulmonary bypass time, right heart failure, and inc
40#
發(fā)表于 2025-3-28 13:16:13 | 只看該作者
Chronic Management of Patients with Left Ventricular Assist Devices,g this event, the FDA approved implantable LVADs in 1994 as a bridge to transplantation. Due to a perpetual shortage of available organ donors for end-stage congestive heart failure (CHF) patients, durable LVAD implantation is now also used for destination therapy (DT) since 2002 after it received a
 關(guān)于派博傳思  派博傳思旗下網(wǎng)站  友情鏈接
派博傳思介紹 公司地理位置 論文服務流程 影響因子官網(wǎng) 吾愛論文網(wǎng) 大講堂 北京大學 Oxford Uni. Harvard Uni.
發(fā)展歷史沿革 期刊點評 投稿經(jīng)驗總結(jié) SCIENCEGARD IMPACTFACTOR 派博系數(shù) 清華大學 Yale Uni. Stanford Uni.
QQ|Archiver|手機版|小黑屋| 派博傳思國際 ( 京公網(wǎng)安備110108008328) GMT+8, 2025-10-25 21:32
Copyright © 2001-2015 派博傳思   京公網(wǎng)安備110108008328 版權(quán)所有 All rights reserved
快速回復 返回頂部 返回列表
镇原县| 古交市| 台北市| 罗定市| 高安市| 长顺县| 开化县| 锡林浩特市| 日土县| 德保县| 洪洞县| 宜良县| 阜宁县| 天水市| 铜川市| 牡丹江市| 醴陵市| 登封市| 宕昌县| 衡山县| 区。| 万年县| 中宁县| 宜黄县| 项城市| 防城港市| 桦南县| 察哈| 诏安县| 普定县| 中卫市| 宝鸡市| 乐都县| 运城市| 钟祥市| 井研县| 阆中市| 灵山县| 龙州县| 项城市| 阿拉善右旗|